ERBB2 and neoplasm: We have found that polyclonal anti-HER2 antibodies (HER2-VIA) generated by vaccinating mice with an adenovirus expressing human HER2 can retard the growth of established HER2-positive human tumor xenografts in vivo, bind to HER2 at the plasma membrane, induce HER2 internalization, ubiquitination and degradation, and eventually inactivate downstream kinase Akt.